

Regimen Name	Cancer Type	Pathway Pathologies	Pathway Stages	Pathway BioMarkers	Pathway Line of Treatment	Consensus Group(s)
Zytiga (Abiraterone Acetate) and Prednisone (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate) (1000 mg); Prednisone and Zoladex (Goserelin) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate); Prednisone and Lupron (Leuprolide Acetate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate); Prednisone and Trelstar (Triptorelin Pamoate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	FDA; NCCN Category 1

Zytiga (Abiraterone Acetate) and Prednisone (Castration Resistant; Metastatic; First Line)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line	FDA; NCCN Category 1; NCCN Category 2A
Zytiga (Abiraterone) (1000mg) and Prednisone (Metastatic; Second Line or Greater)	Prostate	Adenocarcinoma	IVB; Recurrent		Second Line +	FDA; NCCN Category 1; NCCN Category 2A; NCCN Category 2B
Zytiga (Abiraterone Acetate) with Zoladex (Goserelin Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line +	
Zytiga (Abiraterone Acetate) with Lupron (Leuprolide Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line +	

<p>Zytiga (Abiraterone Acetate) with Trelstar (Triptorelin Pamoate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)</p>	<p>Prostate</p>	<p>Adenocarcinoma</p>	<p>IVB; Recurrent</p>	<p>Castration-resistant - Yes</p>	<p>First Line +</p>	
<p>Arimidex (Anastrozole) (Palliative; Stage IV or Recurrent)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 2A; NCI-PDQ</p>

<p>Arimidex (Anastrozole) With Monthly Zoladex (Goserelin)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 2A</p>
--	---------------	---	----------------------	---	---------------------	-------------------------

<p>Arimidex (Anastrozole) with Monthly Leuprolide (3.75 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 2A</p>
---	---------------	---	----------------------	---	---------------------	-------------------------

<p>Arimidex (Anastrozole) with Monthly Leuprolide (7.5 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 2A</p>
<p>Erleada (Apalutamide) (Castration Sensitive; Metastatic/Recurrent First Line or Greater)</p>	<p>Prostate</p>	<p>Adenocarcinoma</p>	<p>IVB; Recurrent</p>	<p>Castration-resistant - No</p>	<p>First Line +</p>	<p>NCCN Category 1</p>
<p>Erleada (Apalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)</p>	<p>Prostate</p>	<p>Adenocarcinoma</p>	<p>IVB, Recurrent</p>	<p>Castration-resistant - No</p>	<p>First Line +</p>	<p>NCCN Category 1</p>

Erleada (Apalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	NCCN Category 1
Erleada (Apalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	NCCN Category 1
Clarithromycin and Amoxicillin (Gastric MALT; H-Pylori Positive; First Line) (W)	Lymphoma/ Lymphoproliferative Diseases	MALT - Gastric	IA-E, IB-E, IIA-E, IIB-E		First Line	
Clarithromycin and Metronidazole (Gastric MALT; H-Pylori Positive; First Line)	Lymphoma/ Lymphoproliferative Diseases	MALT - Gastric	IA-E, IB-E, IIA-E, IIB-E		First Line	
Xtandi (Enzalutamide) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	FDA; NCCN Category 1

Xtandi (Enzalutamide) (Metastatic; 1st Line)	Prostate	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line	ASCO; FDA; NCCN Category 1; NCI-PDQ
Xtandi (Enzalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	NCCN Category 1
Xtandi (Enzalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	NCCN Category 1
Xtandi (Enzalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	NCCN Category 1

<p>Aromasin (Exemestane) (Stage IV or Recurrent; Palliative)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive</p>	<p>Second Line +</p>	<p>NCCN Category 2A; NCI-PDQ</p>
--	---------------	---	----------------------	--	----------------------	--------------------------------------

<p>Aromasin (Exemestane) With Monthly Goserelin</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>NCCN Category 2A; NCI-PDQ</p>
---	---------------	---	----------------------	---	--	--------------------------------------

<p>Aromasin (Exemestane) With Monthly Leuprolide (3.75 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>NCCN Category 2A; NCI-PDQ</p>
--	---------------	---	----------------------	---	--	--------------------------------------

<p>Aromasin (Exemestane) With Monthly Leuprolide (7.5 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>NCCN Category 2A; NCI-PDQ</p>
---	---------------	---	----------------------	---	--	--------------------------------------

Faslodex (Fulvestrant) 500 mg	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Estrogen Receptor - Positive	First Line +	NCCN Category 1; NCCN Category 2A
----------------------------------	--------	--	---------------	---	--------------	--------------------------------------

Faslodex (Fulvestrant) (No Prior Endocrine Therapy)	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive	First Line +	FDA; NCCN Category 1
---	--------	--	---------------	--	--------------	-------------------------

<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment With Goserelin</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 1; NCCN Category 2A</p>
---	---------------	---	----------------------	---	---------------------	--

<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (3.75 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 1; NCCN Category 2A</p>
---	---------------	---	----------------------	---	---------------------	--

<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (7.5 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 1; NCCN Category 2A</p>
--	---------------	---	----------------------	---	---------------------	--

<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 1; NCCN Category 2A</p>
--	---------------	---	----------------------	---	---------------------	--

Faslodex (Fulvestrant) with Monthly Goserelin	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	NCCN Category 1; NCCN Category 2A
--	--------	--	---------------	--	--------------	--------------------------------------

<p>Faslodex (Fulvestrant) with Monthly Leuprolide (3.75 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 1; NCCN Category 2A</p>
---	---------------	---	----------------------	---	---------------------	--

Faslodex (Fulvestrant) with Monthly Leuprolide (7.5 mg)	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	NCCN Category 1; NCCN Category 2A
Zoladex (Goserelin Acetate) (For 1-3 Years) (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) for 1-3 years with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A; NCI-PDQ

Zoladex (Goserelin Acetate) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	AUA; NCCN Category 2A
Zoladex (Goserelin Acetate) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	AUA; NCCN Category 2A
Zoladex (Goserelin Acetate) For 6 months (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCI-PDQ
Zoladex (Goserelin Acetate) For 6 months with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCI-PDQ
Zoladex (Goserelin Acetate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	ASCO; FDA; NCCN Category 2A; NCI-PDQ

Zoladex (Goserelin Acetate) Post Prostatectomy with Positive Nodes	Prostate	Adenocarcinoma	IVA		Adjuvant/ Post-operative	NCCN Category 1
Zoladex (Goserelin Acetate) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) with Bicalutamide or Flutamide (Up to 60 Days for Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent		First Line +	ASCO; FDA; NCCN Category 2A

<p>Femara (Letrozole) (Stage IV or Recurrent; Palliative)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>FDA; NCCN Category 2A</p>
---	---------------	---	----------------------	--	---------------------	------------------------------

Femara (Letrozole) with Monthly Goserelin	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	NCCN Category 2A
---	--------	--	---------------	--	--------------	------------------

<p>Femara (Letrozole) with Monthly Leuprolide (3.75 mg)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>NCCN Category 2A</p>
---	---------------	---	----------------------	---	---------------------	-------------------------

Femara (Letrozole) With Monthly Leuprolide (7.5 mg)	Breast	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	NCCN Category 2A
Eligard (Leuprolide) 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A
Lupron (Leuprolide) For 1-3 Years (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A

Lupron (Leuprolide) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Lupron (Leuprolide) For 4-6 Months (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCI-PDQ
Lupron (Leuprolide) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	NCCN Category 2A
Lupron (Leuprolide) For 4-6 Months with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCI-PDQ

Lupron (Leuprolide) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	NCCN Category 2A
Lupron (Leuprolide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Lupron (Leuprolide Acetate) Post Prostatectomy with Positive Nodes	Prostate	Adenocarcinoma	IVA		Adjuvant/ Post-operative	NCCN Category 1
Lupron (Leuprolide) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	ASCO; FDA; NCCN Category 2A
Lupron (Leuprolide Acetate) with Bicalutamide or Flutamide (Up to 60 Days For Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent		First Line +	ASCO; FDA; NCCN Category 2A

<p>Tamoxifen (Stage IV or Recurrent; 1st Line or Greater)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Menopausal Status - Pre-menopausal</p>	<p>First Line +</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>
<p>Tamoxifen (Recurrent; First Line or Greater)</p>	<p>Ovarian</p>	<p>Adenocarcinoma; Cystadenocarcinoma; Endometroid Carcinoma; Epithelial Cancer; Mucinous Cystadenocarcinoma; Primary Peritoneal; Serous Cystadenocarcinoma</p>	<p>Recurrent</p>	<p>Platinum Resistant/Refractory - Yes</p>	<p>First Line +</p>	<p>NCCN Category 2A; NCCN Category 2B; NCI-PDQ</p>

<p>Tamoxifen with Monthly Goserelin (Premenopausal; Stage IV or Recurrent; 1st Line or Greater)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>
---	---------------	---	----------------------	---	---------------------	---------------------------------------

<p>Tamoxifen with Monthly Leuprolide (7.5 mg) (Stage IV or Recurrent; 1st Line or Greater) (W)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>
--	---------------	---	--	---	---------------------	---------------------------------------

<p>Tamoxifen with Monthly Lupron (Leuprolide Acetate) (3.75) (Stages I-IV/Recurrent; 1st Line or Greater)</p>	<p>Breast</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>
<p>Trelstar (Triptorelin) Post Prostatectomy with Positive Nodes</p>	<p>Prostate</p>	<p>Adenocarcinoma</p>	<p>IVA</p>		<p>Adjuvant/ Post-operative</p>	<p>NCCN Category 1</p>
<p>Trelstar (Triptorelin Pamoate) (For 1-3 Years) (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)</p>	<p>Prostate</p>	<p>Adenocarcinoma</p>	<p>IIC; III; IIIA; IIIB; IIIC; IVA</p>	<p>Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional</p>	<p>First Line</p>	<p>NCCN Category 1; NCCN Category 2A; NCI-PDQ</p>

Trelstar (Triptorelin Pamoate) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)	Prostate	Adenocarcinoma	IIC; III; IIIA; IIIB; IIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Trelstar (Triptorelin Pamoate) (For 4-6 Months) (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	NCCN Category 2A
Trelstar (Triptorelin Pamoate) (For 4-6 Months) With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Prostate	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	NCCN Category 2A
Trelstar (Triptorelin Pamoate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	ASCO; FDA; NCCN Category 2A; NCI-PDQ

Trelstar (Triptorelin Pamoate) with Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	ASCO; FDA; NCCN Category 2A
Trelstar (Triptorelin Pamoate) with Bicalutamide or Flutamide (Up to 60 Days For Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Prostate	Adenocarcinoma	IVB, Recurrent		First Line +	ASCO; FDA; NCCN Category 2A